Order Careers Contact Us Sign in Adaptive Biotechnologies Order Careers
Contact Us Sign in Immune Profiling Platform Platform OverviewPublications
Products & Services LIFE SCIENCES RESEARCHimmunoSEQ®CLINICAL
DIAGNOSTICSclonoSEQ®PipelineDRUG DISCOVERYCellular TherapyVaccines
PARTNERSHIPS Cancer Cellular TherapyAntigen MapBiopharma PartnershipsStrategic
Collaborators About Us Our StoryCultureCareersNewsroomContact Us About Us
Newsroom Press News Features Events Contact Media Relations TOP PRESS RELEASES
01/04/2019 Adaptive Biotechnologies to Enter Into Worldwide Collaboration and
License Agreement with Genentech to Develop Personalized Cellular Therapies
for the Treatment of Cancer 01/03/2019 Adaptive Biotechnologies to Present at
the 37th Annual J.P. Morgan Healthcare Conference 09/28/2018 FDA Grants De
Novo Designation for Adaptive Biotechnologies’ clonoSEQ Assay to Detect and
Monitor Minimal Residual Disease (MRD) in Patients with Multiple Myeloma and
Acute Lymphoblastic Leukemia LATEST PRESS RELEASES 09/25/2013 Sequenta Expands
Sample Types Accepted for ClonoSIGHT MRD Test for Leukemia and Lymphoma
09/19/2013 Adaptive Biotechnologies CEO in “Fireside Chat” at Harvard Medical
School Cancer Advance Conference; Discussing Company’s Pipeline of
Immunotherapy Diagnostics 09/19/2013 Sequenta Develops Novel Method for
Identifying Antigen-Specific T Cells by Combining Conventional Immune
Monitoring Assays with High-Throughput Repertoire Sequencing 09/13/2013
Adaptive Biotechnologies Receives $2.53 million Phase II SBIR to Develop Test
to Identify Cancer Patients at Risk of Death by Infection after Cord Blood
Transplants 07/12/2013 National Public Radio Covers Adaptive in Science News
Segment 07/08/2013 Adaptive CEO Robins speaking at Life Sciences Innovation
Northwest Conference in Seattle 06/27/2013 Adaptive Biotechnologies and Biogen
Idec Sign Immunological Services Agreement 06/12/2013 Sequenta Collaborators
to Present Five Studies Showing the Power of LymphoSIGHT Minimal Residual
Disease Platform at EHA 06/11/2013 CEO Robins Joins distinguished panel on
personalized medicine at Boston CEO conference Previous 1 … 10 11 12 … 15 Next
TOP NEWS FEATURES 01/04/2019 Genentech: A New Age for Neoantigens 01/03/2019
Microsoft Blog: Every immune system has a story to tell; the key is knowing
how to listen 05/09/2018 T Cell Receptor Sequencing IDs Aggressive Lymphoma
Subtype LATEST NEWS FEATURES 09/01/2010 CNN: Differences found in individuals’
immune systems 04/08/2010 Puget Sound Business Journal: Adaptive
Biotechnologies raises $105M 03/26/2010 Adaptive TCR, a Fred Hutch Spinoff,
nabs $4.5M to uncover Immune System Secrets. Previous 1 … 10 11 TOP EVENTS
01/03/2019 J.P. Morgan Healthcare Conference 2019 12/01/2018 ASH 2018 LATEST
EVENTS Contact media relations phone (917) 912-7195 email
media@adaptivebiotech.com Corporate/Research (855) 466-8667 Diagnostics (888)
522-8988 Immune Profiling PlatformPlatform Overview Publications Products &
ServicesLIFE SCIENCES RESEARCH immunoSEQ® CLINICAL DIAGNOSTICS clonoSEQ®
Pipeline DRUG DISCOVERY Cellular Therapy Vaccines PartnershipsCancer Cellular
Therapy Antigen Map Biopharma Partnerships Strategic Collaborators About UsOur
Story Culture Careers News & Events Contact Us © Adaptive Biotechnologies. All
Rights Reserved. Terms of Use Online Privacy Policy Privacy Shield Policy
HIPAA Policy Code of Conduct Patents & Trademarks Licenses